Alostil 5% is generally used for managing symptoms related to progressive hair thinning. The main therapeutic area for the 5% concentration is addressing symptoms associated with androgenetic alopecia, often referred to as male-pattern baldness.

Minoxidil, an active substance, is generally applied to help ease the overall symptom burden associated with hair thinning. This medicine is indicated for the treatment of moderate androgenetic alopecia in adult male subjects, a condition characterized by periods of heightened symptoms that can become more disruptive. The primary indications for its use are symptoms related to male-pattern hair loss and androgenetic alopecia. It is commonly used to help with symptoms that become more noticeable. This therapy may assist with maintaining functional stability and supports patients during difficult episodes by easing distress.

“This activity may help patients cope more steadily with symptom fluctuations and contributes to improved day-to-day comfort.”

Quick Fact: Relief for symptoms related to physical discomfort

Regulatory References

1. Public Assessment Report by the UK's MHRA

The use of Alostil 5% (Minoxidil 5% topical solution) is narrowly defined by official regulatory documentation and is subject to strict eligibility rules concerning age, gender, and pre-existing health conditions. The product is permitted solely for adult men between the ages of 18 and 65 years who have been diagnosed with hereditary pattern hair loss (alopecia androgenetica).

Eligibility Status	Defined Population
Permitted Use	Adult men aged 18 to 65 years with diagnosed hereditary pattern hair loss.
Contraindicated	Women; individuals with known arterial hypertension or cardiovascular disease; patients with irritated, infected, or damaged scalps; and those with Minoxidil hypersensitivity.
Not Recommended	Children and adolescents under 18 years, and adults over 65 years, as regulatory data has not established safety or effectiveness for these age groups.

Use is further restricted to exclude sudden, patchy, or unexplained forms of hair loss, and the medicine is strictly contraindicated during both pregnancy and breastfeeding. Patients with a history of heart disease are advised that use requires special consideration.

Interactions with other medicines and products

The official interaction profile for Alostil 5% is predominantly defined by label-based restrictions concerning its topical application. The most critical regulatory constraint is that the medicine must not be used concurrently with any other medicinal product applied directly to the scalp. This restriction directly addresses the risk of pharmacokinetic alterations.

Exposure-Modifying Interactions

Several exposure-modifying interactions are officially documented. Substances that alter the skin barrier, such as topical retinoids (Tretinoin), anthralin, dithranol, or petrolatum, have been shown to enhance the percutaneous absorption of Minoxidil, thereby increasing systemic exposure. Conversely, co-administration with low-dose acetylsalicylic acid may diminish the therapeutic effectiveness of the topical solution.

Systemic Pharmacodynamic Risks

Minoxidil’s minimal systemic absorption creates a theoretical possibility of a pharmacodynamic interaction. This risk involves the potential for an additive blood pressure-lowering effect when co-administered with systemic antihypertensive agents or peripheral vasodilators (e.g., Guanethidine). This effect may potentiate orthostatic hypotension. For specific patient populations, co-use with systemic Cyclosporine is associated with the exacerbation of hypertrichosis.

Timing-Based Restrictions

Regulatory information also notes that Alostil 5% should not be applied within 24 hours before or after hair treatment procedures, including coloring, permanents, or relaxers.

Modulation of Local Blood Flow

The drug works primarily as a potassium channel opener (KATP channel agonist) on the smooth muscle of tiny blood vessels in the scalp. By activating these channels, it causes the local vasculature to relax and expand (vasodilation), which directly increases microcirculation to the hair structures. This physiological effect increases the supply of oxygen, nutrients, and growth factors to the hair follicle, addressing the high metabolic demands of the active hair growth phases.

Direct Hair Follicle Stimulation

Beyond enhancing blood supply, the medication acts on the epithelial cells of the hair follicle itself. It modulates key signaling pathways to promote cell survival and multiplication (proliferation), facilitating the metabolic activity of the hair matrix. This mechanism directly influences the hair’s natural growth cycle by facilitating the shift of resting follicles into the active growth (anagen) phase and prolonging the duration of that growth stage, which results in a greater number of hair structures entering and remaining in the active growth phase.

How to Use Alostil 5% — Official Administration Guidelines

Alostil 5% is a cutaneous solution that is used for continuous, long-term management according to specific regulatory guidelines. The medicine is designated solely for topical application to the affected areas of the scalp. The administration protocol is rigidly defined by a fixed daily dose and frequency, which must be adhered to for continued use.

---

Standard Labeled Use and Regimen

The standard dose volume is 1 millilitre (mL) of the solution per application. The frequency is twice daily (B.I.D.), with one application in the morning and one in the evening. The total amount administered in any 24-hour period must not exceed 2 mL. Application is measured using the provided dosing apparatus, such as a metered dropper or pump.

---

Administration Conditions and Duration

For proper administration, the solution must be applied only when the hair and scalp are thoroughly dry. The application is strictly limited to the scalp, and regulatory documentation instructs against applying the product to other areas of the body. If an application is missed, users should resume the standard twice-daily schedule with the next planned application and should not attempt to apply extra solution to compensate for the omission. The preparation is intended for continuous long-term use; if administration is stopped, a relapse to the pre-treatment condition is generally observed within three to four months.

---

Population Restrictions

Usage of the 5% concentration is restricted to adult men between the ages of 18 and 65 years for the management of male-pattern hair loss.

Research evidence / Overview of Studies for Alostil 5%

Evidence for Use in Androgenetic Alopecia (AGA) in Men

The research base for Alostil 5% solution includes pivotal randomized controlled trials (RCTs). These types of studies are important for evidence assessment and were used in research exploring how symptoms change over time. In these trials, researchers examined various outcomes, including non-vellus (terminal) hair count and overall Investigator Global Assessments (IGA) of hair coverage. The research focused on adult men with moderate hair loss, particularly at the crown of the head. The findings describe patterns observed in the studies during intermediate follow-up periods, typically up to 48 weeks, highlighting changes measured when comparing the 5% solution to an inactive liquid. Findings also indicate data show patterns related to patient-reported outcomes describing perceived discomfort linked to hair thinning.

Comparing Evidence: Minoxidil 5% Versus Other Treatments

This section will describe the existence of trials that evaluated the 5% concentration versus an inactive substance (placebo) and versus the lower 2% concentration in controlled clinical settings. This evaluation was applied in trials assessing short-term symptom patterns related to hair loss. Studies report how symptoms evolved when the 5% solution was observed against these comparators over defined time intervals. This research provides insight into short-term changes and helps contextualize the measured outcomes.

Long-Term Research and Durability of Response

While the research provides context for the intermediate phase, long-term effects are not fully established. The key controlled trials typically monitored study populations for durations of up to 48 weeks; therefore, the follow-up durations were limited. This means there is limited information for long-term outcomes regarding the maintenance of any changes or the long-term patterns of use. Research is ongoing, but the most detailed data primarily research describes short-term changes.

Research in Special Populations

The research applied in studies examining patient-reported experiences for Alostil 5% generally focuses on a defined demographic. Data for certain groups remain insufficient, and the results apply only to the populations studied—primarily adult men aged 18 to 49 with moderate, vertex hair loss. Specific evidence is limited when considering groups such as older adults (over 65) or individuals with certain underlying medical conditions. Regulatory documents indicate that data for certain subgroups remain insufficient outside of the main study cohort. Therefore, research provides context but not individual predictions.

Consistency and Gaps in the Evidence

The data show patterns related to how Minoxidil 5% was studied for androgenetic alopecia. The research provides context on what has been observed so far, highlighting what is known—and what is still uncertain—about the solution's effects as measured in trials. A key limitation is that study results reflect the specific conditions under which they were conducted. Furthermore, while the evidence suggests certain patterns, the research does not determine whether an individual will respond similarly, as findings were mixed regarding the percentage of individuals who were classified as ‘responders’ in the trials. The variability in measured changes across individual subjects is a pattern that studies have monitored but which is not yet fully understood.

Key Studies & References

1. Label: 5% MINOXIDIL TOPICAL SOLUTION - DailyMed - NIH (Regulatory/Indication Documentation)
2. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men

Common questions about Alostil 5% (FAQ)

Q: What should I do if I miss an application of Alostil 5%?

A: If an application is missed, official product information indicates that users should not attempt to apply extra solution to compensate for the omission. The standard application schedule should be resumed with the next planned application.

Q: How does Alostil 5% stimulate hair growth?

A: Official regulatory documents explain that the medicine influences the hair growth cycle by promoting cell activity and enhancing local blood supply to the hair follicles. This mechanism supports the delivery of oxygen and nutrients and helps prolong the active growth phase of the hair.

Q: When should I apply the solution—hair wet or dry?

A: According to the official administration guidelines, the preparation is required to be applied only when the hair and scalp are thoroughly dry. This condition is required for proper administration of the medicine.

Q: How long does it take for Alostil 5% to work and show results?

A: Regulatory documentation notes that the onset of visible changes for individuals can vary. Studies generally monitored patterns observed during intermediate follow-up periods. Official information indicates that if administration is stopped, a relapse to the pre-treatment condition is generally observed within three to four months.

Q: What are the most common side effects of Alostil 5%?

A: The majority of documented adverse reactions are categorized as Very Common or Common in official safety information. These effects generally involve the skin, such as localized pruritus (itching), erythema (redness), and dermatitis at the application site. Headache is also noted as a very common effect.

Q: Can I use Alostil 5% if I have high blood pressure?

A: Official documentation lists individuals with known arterial hypertension or pre-existing cardiovascular disease as a contraindication, meaning the product is restricted or not permitted for use in those populations. It is important that the full eligibility criteria outlined in the official product labeling be reviewed.

Q: Can I use Alostil 5% if I am taking other blood pressure medications?

A: Regulatory information notes a theoretical possibility of a pharmacodynamic interaction with systemic antihypertensive agents (blood pressure medications) or peripheral vasodilators. Official documentation notes that this may potentiate orthostatic hypotension, which is a form of low blood pressure.

Q: Can I use a hair dryer to dry my hair after applying Alostil 5%?

A: The solution is officially classified as Flammable and must be kept away from all ignition sources, including fire and flame, during storage and use. It is important that all labeled instructions regarding product flammability are followed.

Q: What is the difference between the 2% and 5% concentrations?

A: The 5% concentration is a higher-strength solution containing a greater amount of the active ingredient, Minoxidil. The 5% concentration is indicated for use by adult men with hereditary pattern hair loss, and official guidelines state this concentration is generally not indicated for use in women.

Q: Is Alostil 5% a cure for hair loss?

A: The preparation is recognized for its ability to intervene in the progression of hair thinning and loss. It is intended for continuous long-term management and is not described in official labeling as a cure.

How to Store and Dispose of Alostil 5%

The official storage conditions for Alostil 5% (Minoxidil 5% topical solution/foam) are strictly defined by regulatory documents, focusing on stability and safety concerns, particularly due to the product's flammability.

Storage Requirements

• Temperature: Store the product at Controlled Room Temperature, which is maintained between 20 C and 25 C (68 F to 77 F).
• Flammability: The solution is classified as Flammable and must be kept away from fire or flame and all other ignition sources during storage and use. The container for the aerosol foam is pressurized and must not be punctured or incinerated.
• Protection: The container must be kept tightly closed when not in use. It is also required to keep the medicine out of the reach of children.

Disposal Instructions

Unused or expired Alostil 5% must not be thrown away via wastewater or household waste. Official guidance instructs that the medicine should be returned to a pharmacist for appropriate disposal to protect the environment. If accidentally swallowed, immediately contact a Poison Control Center.